ALNY$320.13
$326.47
Chart
Performance
Key Stats
AI ALNY Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyAlnylam Pharmaceuticals exhibits strong growth potential driven by its innovative RNAi therapeutics pipeline. While currently unprofitable, its expanding product portfolio and strategic partnerships present a compelling long-term investment case. Technicals suggest a cautious approach due to recent price action, but the underlying fundamentals remain robust.
Thematic
Alnylam is a pioneer in RNA interference (RNAi) therapeutics, a rapidly growing field targeting a wide range of diseases previously considered untreatable. The company's focus aligns with major healthcare trends like personalized medicine and novel treatment modalities.
Fundamental
Alnylam is experiencing significant revenue growth, driven by its commercialized products. However, it remains unprofitable due to high R&D expenses, typical for a growth-stage biotech. The balance sheet is solid, with substantial cash and manageable debt, providing runway for continued development.
Technical
The stock has shown a strong upward trend over the past year, but recent performance indicates some consolidation. Key moving averages suggest a longer-term bullish sentiment, but shorter-term indicators show mixed signals, suggesting potential for sideways movement or a minor pullback before further upside.
| Factor | Score |
|---|---|
| RNAi Therapeutics Advancement | 95 |
| Rare Disease Market | 90 |
| Biotechnology Innovation | 85 |
| Healthcare Policy & Reimbursement | 65 |
| Competitive Landscape | 70 |
| Factor | Score |
|---|---|
| Revenue Growth | 85 |
| Profitability | 40 |
| Valuation | 45 |
| Balance Sheet Health | 80 |
| Cash Flow | 50 |
| Factor | Score |
|---|---|
| Trend Analysis | 75 |
| Moving Averages (Daily) | 55 |
| Momentum (Daily) | 50 |
| Volume Analysis | 60 |
| Support/Resistance | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Strong Recent Performance
The stock has shown positive performance across multiple timeframes, with 5D: 2.33%, 1M: 3.06%, 6M: 18.53%, YTD: 40.4%, and 1Y: 39.67%. This indicates increasing investor interest and positive market sentiment.
Innovative Biotechnology Focus
Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapeutics, developing novel treatments for genetic diseases. Its diverse pipeline with multiple drugs in various clinical trial phases suggests significant future growth potential.
Bearish Points (7)
Consistent Net Losses
The company has reported consistent net losses over the past few fiscal years (e.g., -$278.16M in 2024, -$440.24M in 2023) and negative EPS in most recent quarters. This indicates that the business model is not yet profitable on a net income basis.
High Price-to-Sales Ratio
The TTM Price-to-Sales (P/S) ratio of 25.3 is exceptionally high, reflecting the market's optimism about future growth, but also suggests a significant risk of downside if growth expectations are not met.
Calendar
July 2025
31
Next Earnings Date
H: $0.70
A: $0.13
L: $-0.72
H: 827.00M
A: 654.25M
L: 562.00M
Profile
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Seasonals
Price Target
333.71 USD
The 39 analysts offering 1 year price forecasts for ALNY have a max estimate of 500.00 and a min estimate of 212.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Major pharmaceutical partner for Alnylam's vutrisiran (ONPATTRO) and global commercialization rights. Significant presence in rare diseases and cardiovascular health.
Weight: 95
Long-standing strategic alliance with Alnylam in rare genetic diseases, including global development and commercialization of fitusiran. Sanofi's Genzyme unit focuses heavily on rare diseases.
Weight: 90
Co-founded by Alnylam scientists; a leading CRISPR/Cas9 gene-editing company with a strong focus on in vivo applications, including ATTR amyloidosis (similar to Alnylam's focus).
Weight: 85
Direct competitor in the RNAi therapeutics space, developing a pipeline of RNAi drugs for various diseases, particularly liver-directed targets.